Eli Lilly & Co. revenues
In 2Q17, Eli Lilly reported revenue growth to ~$5.8 billion, driven by strong performance of its pharmaceuticals products. These products include Effient, Forteo, and Humulin, as well as new products like Cyramza, Jardiance, Taltz, and Trulicity.
The company reported net income of ~$1.0 billion in 2Q17, representing 35.0% growth compared to its net income of $747.7 million in 2Q16.
The company’s US markets reported revenues of ~$3.3 billion during 2Q17, reflecting 15.0% growth compared to its 2Q16 revenues. This growth was driven by the increased sales of pharmaceutical products and companion animal products.
Eli Lilly’s international markets reported revenues of $2.5 billion during 2Q17, a marginal decrease in revenues compared to 2Q16. The decline was driven by lower realized prices for several products, as well as lower sales of Alimta, Cymbalta, and Zyprexa in various markets.
We’ll discuss Eli Lilly’s 2Q17 segment-wise revenues and performance later in this series.
As we noted earlier, Eli Lilly (LLY) surpassed Wall Street analysts’ estimates for revenues and earnings per share during 2Q17. Wall Street estimated revenues of ~$5.5 billion for 3Q17, reflecting 6.1% growth compared to revenues of ~$5.2 billion for 3Q16. Analysts estimate that its 3Q17 EPS could be $1.03 compared to EPS of $0.88 for 3Q16.
For broad-based exposure to the company, investors can consider the Fidelity MSCI Healthcare ETF (FHLC), which holds 2.2% of its total assets in Eli Lilly (LLY). FHLC also holds 5.6% in Pfizer (PFE), 4.9% in Merck & Co. (MRK), and 1.8% in Biogen (BIIB).